Although CA19-9 is frequently used for a clinical blood test to screen for pancreatic cancer,22, 23 the soluble EphA2 fragment appears to be more accurate and has the potential to replace CA19-9 or be used in a complementary manner to overcome the limitations of CA19-9. This evidence concerns the gene EPHA2 and familial pancreatic carcinoma.